KYTX (Kyverna Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.44
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics FCF Margin %?

Kyverna Therapeutics KYTX +2.93% 12 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Kyverna Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kyverna Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-41.60 Mil. Kyverna Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Kyverna Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Kyverna Therapeutics's current FCF Yield % is -29.31%.

The historical rank and industry rank for Kyverna Therapeutics's FCF Margin % or its related term are showing as below:


During the past 5 years, the highest FCF Margin % of Kyverna Therapeutics was -414.50%. The lowest was -525.00%. And the median was -469.75%.

KYTX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Kyverna Therapeutics FCF Margin % Related Terms

Kyverna Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics FCF Margin % Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
-414.50 -525.00 0.00 0.00 0.00

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KYTX vs FDMT, XOMA, OVID: FCF Margin % Comparison

For the Biotechnology subindustry, Kyverna Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's FCF Margin % falls into.


KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kyverna Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-154.845/0
= %

Kyverna Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-41.597/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Kyverna Therapeutics (KYTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyverna Therapeutics and its competitors. According to the industry distribution chart, Kyverna Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Kyverna Therapeutics' FCF Margin % too high?
Kyverna Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Kyverna Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' FCF Margin % compare to FDMT and XOMA?
According to the Biotechnology industry distribution chart, Kyverna Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places Kyverna Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.44
Price